Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Cancer therapeutic medicine capable of killing medicine-resistant tumor cells and tumor stem cells in chemicotherapy

A technology of tumor stem cells and tumor cells, which is applied in the field of cancer treatment drugs, can solve the problems of no public reports, achieve low cost, overcome chemotherapeutic drug resistance and radiotherapy resistance, and prolong survival time

Inactive Publication Date: 2012-11-14
牛旗 +1
View PDF2 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Finding and establishing drugs that can effectively kill tumor stem cells and overcome resistance to radiotherapy and chemotherapy is of great significance for controlling tumors and improving the prognosis of cancer patients. So far, there is no public report in the relevant literature.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Cancer therapeutic medicine capable of killing medicine-resistant tumor cells and tumor stem cells in chemicotherapy
  • Cancer therapeutic medicine capable of killing medicine-resistant tumor cells and tumor stem cells in chemicotherapy
  • Cancer therapeutic medicine capable of killing medicine-resistant tumor cells and tumor stem cells in chemicotherapy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0019] The following animal experiments further illustrate the beneficial effects of the present invention: separate side population cells from A549 / DDP as lung cancer stem cells to verify the killing efficacy of the present invention in vitro. In vivo test The cisplatin-resistant lung adenocarcinoma cell line A549 / DDP was used to subcutaneously inoculate nude mice to establish an animal model of chemotherapy-resistant tumors to study the in vivo efficacy of the present invention in killing drug-resistant tumors. The methods, results and conclusions are as follows:

[0020] 1. Materials and Methods

[0021] 1.1 Cell lines and cell culture

[0022] Human lung adenocarcinoma cells (A549 / CDDP) were purchased from the Cell Bank of the Institute of Biochemical Cells, Chinese Academy of Sciences. Human lung adenocarcinoma A549 / CDDP cells were cultured in high-glucose DMEM (Gibco Company) medium containing 2 μmol cisplatin (Qilu Pharmaceutical Company) and 10% inactivated fetal bo...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a cancer therapeutic medicine capable of killing medicine-resistant tumor cells and tumor stem cells in chemicotherapy and an application thereof. The medicine is characterized by comprising the following components: the liquid medicine in every 100 milliliters contains 2-10ml of absolute ethyl alcohol, 40-50mg of cis-platinum complexes and 90-98ml of sterile water. The medicine is mainly used for local injection of tumors or intravesical therapy of chest, abdomen, pericardial cavity malignant effusion or aerosol inhalation therapy of lung tumors, and is suitable for the therapy of various solid tumors such as lung cancer, liver cancer, pancreatic cancer, ovarian cancer, cervical cancer, mammary cancer, retroperitoneal tumor or retroperitoneal lymph node metastasis, cardia cancer, gastrointestinal malignant cancer, soft tissue sarcoma, glioma and head and neck neoplasm and the medicine-resistant or medicine-sensitive tumor therapy with chest, abdomen, pericardial cavity malignant effusion.

Description

technical field [0001] The present invention relates to a medicine, more specifically a medicine for treating cancer. Background technique [0002] At present, it is believed that cancer stem cells are the root cause of tumor metastasis, recurrence and drug resistance to radiotherapy and chemotherapy, and also the main cause of tumor treatment failure and death. Transmembrane transporters such as ABCG2 can effectively pump chemotherapy drugs out of cells to avoid cell damage, which is the key to drug resistance of tumor stem cells. Finding and establishing drugs that can effectively kill tumor stem cells and overcome resistance to radiotherapy and chemotherapy is of great significance for controlling tumors and improving the prognosis of cancer patients. So far, there is no public report in the relevant literature. Contents of the invention [0003] The purpose of the present invention is to provide a cancer treatment drug capable of killing radiochemotherapy-resistant tu...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K33/24A61K31/337A61K31/17A61K31/282A61K31/7068A61K9/08A61P35/00A61P35/04A61P31/04A61P31/10A61P31/12
Inventor 李倩
Owner 牛旗
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com